Literature DB >> 10723025

The HIV-1 reverse transcription (RT) process as target for RT inhibitors.

H Jonckheere1, J Anné, E De Clercq.   

Abstract

Since the Human Immunodeficiency Virus Type 1 (HIV-1) was identified as the etiologic agent of the Acquired Immune Deficiency Syndrome (AIDS), the HIV-1 reverse transcriptase (RT) has been the subject of intensive study. The reverse transcription entails the transition of the single-stranded viral RNA into double-stranded proviral DNA, which is then integrated into the host chromosome. Therefore, the HIV-1 reverse transcriptase plays a pivotal role in the life cycle of the virus and is consequently an interesting target for anti-HIV drug therapy. In the first section, we describe the complex process of reverse transcription and the different activities involved in this process. We then highlight the structure-function relationship of the HIV-1 reverse transcriptase, which is of great importance for a better understanding of resistance development, a major problem in anti-AIDS therapies. Finally, we summarize the mechanisms of HIV resistance toward various RT inhibitors and the implications thereof for the current anti-HIV drug therapies. Copyright 2000 John Wiley & Sons, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10723025     DOI: 10.1002/(sici)1098-1128(200003)20:2<129::aid-med2>3.0.co;2-a

Source DB:  PubMed          Journal:  Med Res Rev        ISSN: 0198-6325            Impact factor:   12.944


  25 in total

1.  3,4,5-Trisubstituted-1,2,4-4H-triazoles as WT and Y188L mutant HIV-1 non-nucleoside reverse transcriptase inhibitors: docking-based CoMFA and CoMSIA analyses.

Authors:  Elena Cichero; Laura Buffa; Paola Fossa
Journal:  J Mol Model       Date:  2010-10-05       Impact factor: 1.810

2.  Design, synthesis, and biological evaluation of 1-[(2-benzyloxyl/alkoxyl)methyl]-5-halo-6-aryluracils as potent HIV-1 non-nucleoside reverse transcriptase inhibitors with an improved drug resistance profile.

Authors:  Xiaowei Wang; Jianfang Zhang; Yang Huang; Ruiping Wang; Liang Zhang; Kang Qiao; Li Li; Chang Liu; Yabo Ouyang; Weisi Xu; Zhili Zhang; Liangren Zhang; Yiming Shao; Shibo Jiang; Liying Ma; Junyi Liu
Journal:  J Med Chem       Date:  2012-02-17       Impact factor: 7.446

3.  Computational studies of the binding mode and 3D-QSAR analyses of symmetric formimidoester disulfides: a new class of non-nucleoside HIV-1 reverse transcriptase inhibitor.

Authors:  Elena Cichero; Sara Cesarini; Andrea Spallarossa; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2008-12-09       Impact factor: 1.810

4.  Acylthiocarbamates as non-nucleoside HIV-1 reverse transcriptase inhibitors: docking studies and ligand-based CoMFA and CoMSIA analyses.

Authors:  Elena Cichero; Sara Cesarini; Andrea Spallarossa; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-01-20       Impact factor: 1.810

5.  The Effects of Statistical Multiplicity of Infection on Virus Quantification and Infectivity Assays.

Authors:  Bhaven A Mistry; Maria R D'Orsogna; Tom Chou
Journal:  Biophys J       Date:  2018-06-19       Impact factor: 4.033

6.  Predicting anti-HIV activity of 2,3-diaryl-1,3-thiazolidin-4-ones: computational approach using reformed eccentric connectivity index.

Authors:  Vipin Kumar; Satish Sardana; Anil Kumar Madan
Journal:  J Mol Model       Date:  2004-11-03       Impact factor: 1.810

Review 7.  Aptamers in HIV research diagnosis and therapy.

Authors:  Jyoti Bala; Srinivasan Chinnapaiyan; Rajib Kumar Dutta; Hoshang Unwalla
Journal:  RNA Biol       Date:  2018-02-12       Impact factor: 4.652

8.  Reverse transcription complex: the key player of the early phase of HIV replication.

Authors:  Sergey Iordanskiy; Michael Bukrinsky
Journal:  Future Virol       Date:  2007-01-01       Impact factor: 1.831

9.  In vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.

Authors:  Steffen Wildum; Daniela Paulsen; Kai Thede; Helga Ruebsamen-Schaeff; Holger Zimmermann
Journal:  Antimicrob Agents Chemother       Date:  2013-08-19       Impact factor: 5.191

10.  Effects of drug resistance mutations L100I and V106A on the binding of pyrrolobenzoxazepinone nonnucleoside inhibitors to the human immunodeficiency virus type 1 reverse transcriptase catalytic complex.

Authors:  Giada A Locatelli; Giuseppe Campiani; Reynel Cancio; Elena Morelli; Anna Ramunno; Sandra Gemma; Ulrich Hübscher; Silvio Spadari; Giovanni Maga
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.